HK1173957A1 - Anticoagulant antidotes - Google Patents

Anticoagulant antidotes

Info

Publication number
HK1173957A1
HK1173957A1 HK13101025.2A HK13101025A HK1173957A1 HK 1173957 A1 HK1173957 A1 HK 1173957A1 HK 13101025 A HK13101025 A HK 13101025A HK 1173957 A1 HK1173957 A1 HK 1173957A1
Authority
HK
Hong Kong
Prior art keywords
antidotes
anticoagulant
anticoagulant antidotes
Prior art date
Application number
HK13101025.2A
Other languages
English (en)
Chinese (zh)
Inventor
Joanne Van Ryn
John Edward Park
Norbert Hauel
Ulrich Kunz
Tobias Litzenburger
Keith Canada
Sanjaya Singh
Alisa Waterman
Original Assignee
貝林格爾‧英格海姆國際有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42061991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1173957(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 貝林格爾‧英格海姆國際有限公司 filed Critical 貝林格爾‧英格海姆國際有限公司
Publication of HK1173957A1 publication Critical patent/HK1173957A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK13101025.2A 2010-01-20 2013-01-23 Anticoagulant antidotes HK1173957A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10151239 2010-01-20
US38391410P 2010-09-17 2010-09-17
PCT/EP2011/050749 WO2011089183A2 (en) 2010-01-20 2011-01-20 Anticoagulant antidotes

Publications (1)

Publication Number Publication Date
HK1173957A1 true HK1173957A1 (en) 2013-05-31

Family

ID=42061991

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13101025.2A HK1173957A1 (en) 2010-01-20 2013-01-23 Anticoagulant antidotes

Country Status (43)

Country Link
US (3) US8486398B2 (xx)
EP (2) EP3195876A1 (xx)
JP (2) JP5575923B2 (xx)
KR (1) KR101781787B1 (xx)
CN (1) CN102711813B (xx)
AP (1) AP2012006242A0 (xx)
AR (1) AR079944A1 (xx)
AU (1) AU2011208719C1 (xx)
BR (1) BR112012018021B1 (xx)
CA (1) CA2787566A1 (xx)
CO (1) CO6571889A2 (xx)
CY (2) CY1118875T1 (xx)
DK (1) DK2525812T3 (xx)
EA (1) EA028371B1 (xx)
EC (1) ECSP12012105A (xx)
ES (1) ES2614992T3 (xx)
FR (1) FR17C1026I2 (xx)
GE (1) GEP20156341B (xx)
HK (1) HK1173957A1 (xx)
HR (1) HRP20170613T1 (xx)
HU (2) HUE032263T2 (xx)
IL (1) IL219427B (xx)
LT (2) LT2525812T (xx)
LU (1) LUC00028I2 (xx)
MA (1) MA33936B1 (xx)
ME (1) ME02602B (xx)
MX (1) MX2012008360A (xx)
MY (1) MY162323A (xx)
NL (1) NL300882I2 (xx)
NO (2) NO2017034I1 (xx)
NZ (1) NZ599508A (xx)
PE (1) PE20121516A1 (xx)
PL (1) PL2525812T3 (xx)
PT (1) PT2525812T (xx)
RS (1) RS55683B1 (xx)
SG (1) SG182552A1 (xx)
SI (1) SI2525812T1 (xx)
TN (1) TN2012000366A1 (xx)
TW (1) TWI513466B (xx)
UA (1) UA110470C2 (xx)
UY (1) UY33196A (xx)
WO (1) WO2011089183A2 (xx)
ZA (1) ZA201202876B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
ES2634098T3 (es) 2011-01-14 2017-09-26 The Regents Of The University Of California Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
EP2665751A1 (en) * 2011-01-19 2013-11-27 Bayer Intellectual Property GmbH Binding proteins to inhibitors of coagulation factors
SG193552A1 (en) * 2011-03-30 2013-11-29 Boehringer Ingelheim Int Anticoagulant antidotes
EP2785700B1 (en) 2011-11-29 2016-03-09 Perosphere, Inc. Anticoagulant reversal agents
CN105229033B (zh) 2013-03-14 2019-04-23 拜尔健康护理有限责任公司 针对与肝素复合的抗凝血酶β的单克隆抗体
EP3060583A1 (en) 2013-10-25 2016-08-31 Boehringer Ingelheim International GmbH Anticoagulant antidotes
TW201623331A (zh) * 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CN105223348A (zh) * 2014-05-26 2016-01-06 北京九强生物技术股份有限公司 人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
JP6776221B2 (ja) * 2014-07-31 2020-10-28 ヘモネティクス・コーポレーションＨａｅｍｏｎｅｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ 凝固分析を使用した抗凝固剤の検出および分類
WO2016044645A1 (en) * 2014-09-17 2016-03-24 Elmaleh David R Anticoagulant derivatives for cardiovascular imaging
WO2016107605A1 (zh) 2014-12-31 2016-07-07 昆明积大制药股份有限公司 药物组合物及其制备方法
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
BR112020012848A2 (pt) 2017-12-24 2021-01-26 Noile-Immune Biotech, Inc. célula imunocompetente, composição farmacêutica, vetor de expressão, e, método para produzir uma célula imunocompetente.
AU2019233581A1 (en) 2018-03-13 2020-09-03 Cancer Research Technology Limited Anti-CD25 for tumour specific cell depletion
KR20210039985A (ko) * 2018-05-11 2021-04-12 헬시언 테라퓨틱스 인코포레이티드 Gasp-1 과립을 표적으로 하는 결합 단백질 및 키메라 항원 수용체 t 세포, 및 이의 용도
JP7503561B2 (ja) 2018-10-29 2024-06-20 ファーハイ ユーエス インコーポレイテッド 新規ジペプチド化合物及びその使用方法
WO2020180489A1 (en) 2019-03-06 2020-09-10 University Of Rochester Anticoagulant compositions and uses thereof
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
TW202321311A (zh) * 2021-08-02 2023-06-01 日商諾伊爾免疫生物科技股份有限公司 與scFv等之連接子結合的抗體
US11446286B1 (en) * 2022-02-28 2022-09-20 King Faisal University Treatment of fungal infections using dabigatran etexilate

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0654085T3 (da) * 1992-01-23 1997-09-22 Merck Patent Gmbh Monomere og dimere antistof-fragment-fusionsproteiner
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6193969B1 (en) 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
EP0981548A4 (en) 1997-04-30 2005-11-23 Enzon Inc SINGLE CHAIN PROTEINS FIXING ANTIGENS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF
DE19729544A1 (de) * 1997-07-10 1999-01-14 Basf Ag Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1278544A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20070031438A1 (en) * 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
ES2315664T3 (es) 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
DK3078743T3 (da) 2007-09-28 2020-08-10 Portola Pharm Inc Antidoter til faktor xa-inhibitorer og fremgangsmåder til anvendelse af disse
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
JP2013502449A (ja) 2009-08-24 2013-01-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシレート過剰投与による活性炭の緊急処置
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Also Published As

Publication number Publication date
KR20120128126A (ko) 2012-11-26
AU2011208719A1 (en) 2012-05-17
CY2017025I2 (el) 2017-11-14
NO2017034I1 (no) 2017-07-11
RS55683B1 (sr) 2017-07-31
FR17C1026I2 (fr) 2018-07-20
BR112012018021B1 (pt) 2020-12-08
LTPA2017021I1 (lt) 2017-07-25
PT2525812T (pt) 2017-04-26
CA2787566A1 (en) 2011-07-28
EA028371B1 (ru) 2017-11-30
SG182552A1 (en) 2012-08-30
ES2614992T3 (es) 2017-06-02
CY2017025I1 (el) 2017-11-14
LUC00028I1 (xx) 2017-07-14
LTC2525812I2 (lt) 2019-05-10
TN2012000366A1 (en) 2014-01-30
AP2012006242A0 (en) 2012-04-30
US20150210778A1 (en) 2015-07-30
NO2022036I1 (no) 2022-08-12
HRP20170613T1 (hr) 2017-06-30
US8486398B2 (en) 2013-07-16
ME02602B (me) 2017-06-20
MX2012008360A (es) 2012-08-08
PE20121516A1 (es) 2012-11-24
BR112012018021A2 (pt) 2017-06-20
LUC00028I2 (xx) 2017-09-25
JP2014210794A (ja) 2014-11-13
EA201201016A1 (ru) 2013-02-28
EP3195876A1 (en) 2017-07-26
WO2011089183A3 (en) 2011-11-17
ZA201202876B (en) 2012-12-27
HUE032263T2 (en) 2017-09-28
PL2525812T3 (pl) 2017-07-31
WO2011089183A2 (en) 2011-07-28
DK2525812T3 (en) 2017-02-27
KR101781787B1 (ko) 2017-09-26
HUS1700030I1 (hu) 2017-08-28
MY162323A (en) 2017-05-31
NL300882I2 (nl) 2017-07-20
SI2525812T1 (sl) 2017-05-31
AU2011208719C1 (en) 2017-07-13
EP2525812B1 (en) 2017-01-18
CN102711813A (zh) 2012-10-03
ECSP12012105A (es) 2012-10-30
LT2525812T (lt) 2017-02-27
CO6571889A2 (es) 2012-11-30
NZ599508A (en) 2014-05-30
UA110470C2 (ru) 2016-01-12
AR079944A1 (es) 2012-02-29
IL219427A0 (en) 2012-06-28
UY33196A (es) 2011-08-31
IL219427B (en) 2018-05-31
TW201136606A (en) 2011-11-01
US20120027780A1 (en) 2012-02-02
US20130289248A1 (en) 2013-10-31
FR17C1026I1 (fr) 2017-09-08
JP5575923B2 (ja) 2014-08-20
US9034822B2 (en) 2015-05-19
CY1118875T1 (el) 2018-01-10
TWI513466B (zh) 2015-12-21
GEP20156341B (en) 2015-08-10
JP2013517317A (ja) 2013-05-16
CN102711813B (zh) 2015-03-04
MA33936B1 (fr) 2013-01-02
EP2525812A2 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
HUS1700030I1 (hu) Véralvadásgátló-antidótumok
GB201322812D0 (en) No title
ZA201302153B (en) Auto-injector
ZA201302364B (en) Auto-injector
GB201304176D0 (en) No title
GB201508422D0 (en) No Title
GB201406982D0 (en) No title
GB201405882D0 (en) No title
GB201312107D0 (en) No title
EP2535065A4 (en) dialyzer
IL227653A0 (en) Anticoagulant antidotes
EP2976135A4 (en) Trampolines
GB201313383D0 (en) No title
GB201512453D0 (en) No title
GB201411386D0 (en) No title
GB201503046D0 (en) No title
GB201403810D0 (en) No title
GB201110818D0 (en) Balanced switch
GB201009261D0 (en) Trays
AU2011100252A4 (en) Catch the Coasters
GB201400705D0 (en) No title
GB201307218D0 (en) No title
AU2012904850A0 (en) Game
AU2012905329A0 (en) Trampolines
GB201216988D0 (en) No title